ACADIA Pharmaceuticals (LTS:0A4W) Total Equity: $1,248 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A4W ACADIA Pharmaceuticals Inc LTS:0A4W
76 GF Score
Price $26.87
GF Value $26.62
! 9 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Total Equity?

ACADIA Pharmaceuticals LTS:0A4W 76 Total Equity is $1,248 Mil as of Mar. 2026. GuruFocus rates LTS:0A4W with a GF Score™ of 76/100 and a GF Value™ of $26.62. The stock has 9 warning signs investors should review.

ACADIA Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was $1,248 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

ACADIA Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Total Equity Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 540.89 400.41 431.76 732.79 1,227.39

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 765.24 822.38 917.27 1,227.39 1,248.07
LTS:0A4W
76GF Score
ACADIA Pharmaceuticals Inc LTS:0A4W
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

ACADIA Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1564.195-336.805
=1,227

ACADIA Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=1605.23-357.164
=1,248

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $1,248 Mil mean?
ACADIA Pharmaceuticals (LTS:0A4W) has a Total Equity of $1,248 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Total Equity too high?
ACADIA Pharmaceuticals' current Total Equity is $1,248 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Total Equity compare to VKTX and EWTX?
ACADIA Pharmaceuticals' Total Equity of $1,248 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Total Equity is $1,248 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
ACADIA Pharmaceuticals (LTS:0A4W) has a current Total Equity of $1,248 Mil. The stock's GF Value™ is $26.62, compared to a current price of $26.87 — trading 0.9% above its estimated fair value. The current Total Equity is $1,248 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 76/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For ACADIA Pharmaceuticals (LTS:0A4W), the current Total Equity is $1,248 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (LTS:0A4W) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of $26.87 is trading 0.9% above its estimated GF Value™ of $26.62.

Key valuation signals for LTS:0A4W:

  • Total Equity: $1,248 Mil
  • GF Value™: $26.62 vs. price of $26.87 (0.9% above fair value)
  • GF Score™: 76/100 with 9 warning signs

No single metric tells the full story. See the LTS:0A4W stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
76GF Score

Get the complete analysis for LTS:0A4W

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.87
Price
$26.62
GF Value